Randomized phase II study of docetaxel plus zoledronic acid versus docetaxel in patients with relapsing or refractory non-small cell lung cancer and bone metastasis

Randomized phase II study of docetaxel plus zoledronic acid versus docetaxel in patients with relapsing or refractory non-small cell lung cancer and bone metastasis - Docetaxel plus zoledronic acid in patients with NSCLC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001098

Enrollment

100

Registered

2008-03-26

Start date

2007-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Docetaxel plus zoledronic acid Docetaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: >NSCLC with bone metastasis >Previous treatment with one or two chemotherapy regimens >Measurable lesion >Adult patients (>20 years of age) >Performance status 0-2 >Adequate organ functionWritten informed consent

Exclusion criteria

Exclusion criteria: >Previous treatment with docetaxel or zoledronic acid >Regular use of corticosteroidOral complication

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Safety, Response rate, SRE rate, SRE free survival, Over all survival	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026